You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》康灃生物-B(06922.HK)今日起招股 入場費約3,818.1元
阿思達克 12-16 09:24
內地醫療器械公司康灃生物-B(06922.HK)公布招股詳情,擬全球發售1,111萬股H股,其中,香港發售佔10%,國際發售股份為90%。發售價為每股18.9元,每手200股,入場費約3,818.1元;今日(16日)起至下周三(21日)中午公開招股,預期將於12月30日掛牌上市。花旗及華泰國際為聯席保薦人。 集團預計,收取的全球發售所得款項淨額將約為1.4億元,當中73.9%用於研發活動、商業推廣及製造核心產品;6.1%用於心臟冷凍消融系統的研發活動、計劃商業推廣及製造;20%用於目前產品管線的其餘14項產品及在研產品的研發活動、註冊備案、計劃商業推廣及製造。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account